SG10201706045RA - Pertuzumab variants and evaluation thereof - Google Patents

Pertuzumab variants and evaluation thereof

Info

Publication number: SG10201706045RA
Authority: SG; Singapore
Prior art keywords: evaluation; pertuzumab variants; pertuzumab; variants
Prior art date: 2013-04-16

Application number

SG10201706045RA

Inventor

Lynn A Gennaro

Yung-Hsiang Kao

Yonghua Zhang

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-16

Filing date

2014-04-15

Publication date

2017-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694078&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201706045R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-15 Application filed by Genentech Inc filed Critical Genentech Inc

2017-08-30 Publication of SG10201706045RA publication Critical patent/SG10201706045RA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44747—Composition of gel or of carrier mixture
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

SG10201706045RA 2013-04-16 2014-04-15 Pertuzumab variants and evaluation thereof SG10201706045RA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361812603P	2013-04-16	2013-04-16

Publications (1)

Publication Number	Publication Date
SG10201706045RA true SG10201706045RA (en)	2017-08-30

Family

ID=50694078

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10201706045RA SG10201706045RA (en)	2013-04-16	2014-04-15	Pertuzumab variants and evaluation thereof
SG10201911353WA SG10201911353WA (en)	2013-04-16	2014-04-15	Pertuzumab variants and evaluation thereof
SG11201508536PA SG11201508536PA (en)	2013-04-16	2014-04-15	Pertuzumab variants and evaluation thereof

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10201911353WA SG10201911353WA (en)	2013-04-16	2014-04-15	Pertuzumab variants and evaluation thereof
SG11201508536PA SG11201508536PA (en)	2013-04-16	2014-04-15	Pertuzumab variants and evaluation thereof

Country Status (25)

Country	Link
US (7)	US9815904B2 (en)
EP (2)	EP2986643A2 (en)
JP (2)	JP2016522176A (en)
KR (2)	KR20150143649A (en)
CN (1)	CN105121471A (en)
AR (1)	AR095863A1 (en)
AU (3)	AU2014254086B2 (en)
BR (1)	BR112015024926A2 (en)
CA (2)	CA3071678A1 (en)
CL (3)	CL2015003049A1 (en)
CR (1)	CR20150576A (en)
EA (1)	EA201591643A1 (en)
HK (1)	HK1211948A1 (en)
IL (2)	IL241103B (en)
MA (1)	MA38567A1 (en)
MX (2)	MX368259B (en)
MY (1)	MY173295A (en)
NZ (2)	NZ712012A (en)
PE (2)	PE20151769A1 (en)
PH (1)	PH12015502382A1 (en)
RU (2)	RU2737727C2 (en)
SG (3)	SG10201706045RA (en)
TW (1)	TWI554284B (en)
WO (1)	WO2014172371A2 (en)
ZA (1)	ZA201506594B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
TWI472339B (en)	2008-01-30	2015-02-11	Genentech Inc	Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0812682A2 (en)	2008-06-16	2010-06-22	Genentech Inc	metastatic breast cancer treatment
KR20160084500A (en)	2009-10-26	2016-07-13	에프. 호프만-라 로슈 아게	Method for the production of a glycosylated immunoglobulin
BR112015024926A2 (en)	2013-04-16	2017-10-10	Genentech Inc	compositions, article of manufacture, methods for treating a cancer patient, for evaluating a composition, for evaluating biological activity, for producing a composition and for evaluating the fragmentation of a composition and variant of pertuzumab
KR102313262B1 (en) *	2016-12-28	2021-10-14	제넨테크, 인크.	Treatment of advanced HER2-expressing cancer
JP6741875B2 (en)	2017-01-17	2020-08-19	ジェネンテック，インコーポレイテッド	Subcutaneous HER2 antibody preparation
KR102417583B1 (en)	2017-03-02	2022-07-07	제넨테크, 인크.	Adjuvant treatment of her2-positive breast cancer
KR20190140952A (en) *	2017-04-24	2019-12-20	제넨테크, 인크.	ERBB2 / HER2 mutations in transmembrane and proximal membrane domains
WO2019055631A1 (en)	2017-09-13	2019-03-21	Mayo Foundation For Medical Education And Research	Identification and monitoring of acid hydrolysis products of immunoglobulin heavy chains
JP7259778B2 (en)	2020-01-31	2023-04-18	トヨタ自動車株式会社	Vehicles and automated driving systems
CN113189184B (en) *	2021-04-28	2022-09-09	浙江大学	Capillary gel electrophoresis sample buffer solution containing cysteine
AU2022263700A1 (en)	2021-04-29	2023-11-16	Hyslink Therapeutics	Preparation method and application of antibody drug conjugate
KR102511384B1 (en)	2022-04-14	2023-03-16	지용환	The rice swipper that can reduce grain damage

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0171407B1 (en)	1984-01-30	1993-11-18	Imperial Cancer Research Technology Limited	Improvements relating to growth factors
US5401638A (en)	1986-06-04	1995-03-28	Oncogene Science, Inc.	Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en)	1986-12-31	1990-11-06	The Regents Of The University Of California	Determination of status in neoplastic disease
WO1989006692A1 (en)	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en)	1988-01-12	1998-02-24	Genentech, Inc.	In vivo tumor detection assay
ATE155813T1 (en)	1989-05-19	1997-08-15	Genentech Inc	HER2 EXTRACELLULAR DOMAIN
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JP3951062B2 (en)	1991-09-19	2007-08-01	ジェネンテック・インコーポレーテッド	Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US7371376B1 (en)	1996-10-18	2008-05-13	Genentech, Inc.	Anti-ErbB2 antibodies
EP0852951A1 (en)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
PT1864999E (en)	1996-11-27	2009-06-25	Genentech Inc	Affinity purification of polypeptide on protein a matrix
US5994071A (en)	1997-04-04	1999-11-30	Albany Medical College	Assessment of prostate cancer
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
PT1064027E (en)	1998-03-27	2008-09-29	Genentech Inc	Apo-2 ligand-anti-her-2 antibody synergism
NZ507557A (en)	1998-05-06	2003-10-31	Genentech Inc	Protein purification by ion exchange chromatography
US6573043B1 (en)	1998-10-07	2003-06-03	Genentech, Inc.	Tissue analysis and kits therefor
JP5623681B2 (en)	1999-05-14	2014-11-12	ジェネンテック，インコーポレイテッド	Treatment with anti-ErbB2 antibody
MXPA01013395A (en)	1999-06-25	2003-09-04	Genentech Inc	TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES.
US20030086924A1 (en)	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US20040013667A1 (en)	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
SI1210115T1 (en)	1999-08-27	2009-12-31	Genentech Inc	DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en)	2000-03-16	2003-10-14	Genentech, Inc.	Rodent HER2 tumor model
DE60139768D1 (en)	2000-05-19	2009-10-15	Genentech Inc	GENERAL PROCESS FOR IMPROVING THE PROBABILITY OF AN EFFECTIVE RESPONSE TO A K
US6984494B2 (en)	2000-08-15	2006-01-10	Genentech, Inc.	Analytical method
NZ526720A (en)	2000-12-28	2007-11-30	Altus Pharmaceuticals Inc	Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
DK1501856T3 (en)	2002-04-10	2013-03-25	Genentech Inc	Anti-HER2 antibody variants
WO2005117986A2 (en)	2004-06-01	2005-12-15	Genentech, Inc.	Antibody drug conjugates and methods
CA2490758C (en) *	2002-07-15	2014-09-23	Genentech, Inc.	Dosage form of recombinant humanized monoclonal antibody 2c4
EP2332996B1 (en)	2002-09-11	2014-10-15	Genentech, Inc.	Purification of anti-Her2 antibodies
US20040258685A1 (en)	2002-11-21	2004-12-23	Genentech, Inc.	Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
JP5068072B2 (en) *	2003-06-27	2012-11-07	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Modified binding molecule comprising a linking peptide
EP3722309A1 (en)	2003-07-28	2020-10-14	Genentech, Inc.	Reducing protein a leaching during protein a affinity chromatography
WO2005099756A2 (en)	2004-04-08	2005-10-27	Agus David B	ErbB ANTAGONISTS FOR PAIN THERAPY
SV2006002143A (en)	2004-06-16	2006-01-26	Genentech Inc	USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20180091967A (en) *	2004-07-22	2018-08-16	제넨테크, 인크.	Her2 antibody composition
CN101052654A (en)	2004-08-19	2007-10-10	健泰科生物技术公司	Polypeptide variants with altered effector function
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
EP1825001A2 (en)	2004-12-07	2007-08-29	Genentech, Inc.	Selecting patients for therapy with a her inhibitor
MX2007006430A (en)	2004-12-13	2007-07-19	Hoffmann La Roche	Novel pharmaceutical composition containing at least one dolastatin 10 derivative.
CN101141981A (en)	2005-01-21	2008-03-12	健泰科生物技术公司	Fixed dosing of her antibodies
DK1850874T3 (en)	2005-02-23	2013-11-11	Genentech Inc	Extension of time to disease progression or survival for ovarian cancer using pertuzumab
WO2006096861A2 (en)	2005-03-08	2006-09-14	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en)	2005-03-14	2006-09-21	Genentech, Inc.	Animal model of ligand activated HER2 expressing tumors
JP2006316040A (en)	2005-05-13	2006-11-24	Genentech Inc	Herceptin(r) adjuvant treatment
MY157955A (en)	2005-07-06	2016-08-30	Hoffmann La Roche	Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (en)	2005-07-22	2007-03-09	Genentech Inc	COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7700299B2 (en)	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2008015581A (en)	2006-06-05	2008-12-17	Genentech Inc	Extending survival of cancer patients with elevated levels of egf or tgf-alpha.
US8015939B2 (en)	2006-06-30	2011-09-13	Asml Netherlands B.V.	Imprintable medium dispenser
KR101136763B1 (en)	2006-08-21	2012-04-24	에프. 호프만-라 로슈 아게	Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en)	2006-09-15	2008-03-20	F. Hoffmann-La Roche Ag	Tumor therapy with a combination of anti-her2 antibodies
KR20090115980A (en)	2007-03-02	2009-11-10	제넨테크, 인크.	Predicting response to a her dimerisation inhibitor based on low her3 expression
CN103554263B (en) *	2007-03-22	2016-09-28	健泰科生物技术公司	Apoptotic anti-IgE antibodies in conjunction with the IgE that film combines
EP1997534A1 (en)	2007-05-31	2008-12-03	Pierre Fabre Medicament	Cancer treatment combination therapy comprising vinflunine and trastuzumab
MX2009012838A (en)	2007-06-06	2009-12-11	Hoffmann La Roche	Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label.
ES2417148T3 (en)	2007-06-08	2013-08-06	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI3597659T1 (en)	2007-07-09	2023-04-28	Genentech, Inc.	Prevention of disulfide bond reduction during recombinant production of polypeptides
PE20140100A1 (en)	2007-09-12	2014-02-12	Genentech Inc	COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITING COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS
MY188455A (en) *	2007-10-19	2021-12-09	Genentech Inc	Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
ES2666170T3 (en)	2007-10-30	2018-05-03	Genentech, Inc.	Purification of antibodies by cation exchange chromatography
TWI472339B (en)	2008-01-30	2015-02-11	Genentech Inc	Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
JP2011511777A (en) *	2008-01-30	2011-04-14	アボット・ラボラトリーズ	Compositions and methods for crystallizing antibody fragments
CA2716670A1 (en)	2008-03-06	2009-09-11	Genentech, Inc.	Combination therapy with c-met and her antagonists
KR20210131473A (en)	2008-03-18	2021-11-02	제넨테크, 인크.	Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
BRPI0812682A2 (en)	2008-06-16	2010-06-22	Genentech Inc	metastatic breast cancer treatment
FR2942799B1 (en) *	2009-03-06	2011-02-25	Lfb Biotechnologies	ANTI-RHESUS MONOCLONAL ANTIBODY
SG176073A1 (en)	2009-05-29	2011-12-29	Hoffmann La Roche	Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
JP5680671B2 (en) *	2009-12-22	2015-03-04	ロシュグリクアートアーゲー	Anti-HER3 antibody and use thereof
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
BR112013014316A2 (en)	2010-12-09	2016-09-27	Genentech Inc	her2-positive cancer treatment with paclitaxel and trastuzumab-mcc-dm1
JOP20210044A1 (en) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-cd38 antibodies
WO2012100343A1 (en) *	2011-01-28	2012-08-02	National Research Council Of Canada	Engineering of immunoglobulin domains
EP2683413A1 (en)	2011-03-07	2014-01-15	F.Hoffmann-La Roche Ag	In vivo selection of therapeutically active antibodies
KR20230028585A (en)	2011-10-14	2023-02-28	제넨테크, 인크.	Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013083810A1 (en)	2011-12-09	2013-06-13	F. Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
US20130195851A1 (en)	2011-12-23	2013-08-01	Genentech, Inc.	Articles of manufacture and methods for co-administration of antibodies
SG10201706196XA (en)	2012-06-08	2017-08-30	Hoffmann La Roche	Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014083178A1 (en)	2012-11-30	2014-06-05	F. Hoffmann-La Roche Ag	Identification of patients in need of pd-l1 inhibitor cotherapy
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
BR112015024926A2 (en)	2013-04-16	2017-10-10	Genentech Inc	compositions, article of manufacture, methods for treating a cancer patient, for evaluating a composition, for evaluating biological activity, for producing a composition and for evaluating the fragmentation of a composition and variant of pertuzumab
CN105934253A (en)	2013-12-17	2016-09-07	豪夫迈·罗氏有限公司	Methods of treating HER2-positive cancers using pd-1 axis binding antagonists and anti-HER2 antibodies

2014
- 2014-04-15 BR BR112015024926A patent/BR112015024926A2/en active Search and Examination
- 2014-04-15 WO PCT/US2014/034200 patent/WO2014172371A2/en active Application Filing
- 2014-04-15 MX MX2015013898A patent/MX368259B/en active IP Right Grant
- 2014-04-15 KR KR1020157032283A patent/KR20150143649A/en active Application Filing
- 2014-04-15 KR KR1020207019835A patent/KR20200085942A/en not_active Application Discontinuation
- 2014-04-15 TW TW103113741A patent/TWI554284B/en active
- 2014-04-15 US US14/253,038 patent/US9815904B2/en active Active
- 2014-04-15 PE PE2015002163A patent/PE20151769A1/en unknown
- 2014-04-15 CN CN201480020921.2A patent/CN105121471A/en active Pending
- 2014-04-15 JP JP2016509031A patent/JP2016522176A/en not_active Withdrawn
- 2014-04-15 SG SG10201706045RA patent/SG10201706045RA/en unknown
- 2014-04-15 MY MYPI2015002532A patent/MY173295A/en unknown
- 2014-04-15 MA MA38567A patent/MA38567A1/en unknown
- 2014-04-15 AR ARP140101600A patent/AR095863A1/en unknown
- 2014-04-15 EP EP14723656.6A patent/EP2986643A2/en not_active Withdrawn
- 2014-04-15 CA CA3071678A patent/CA3071678A1/en not_active Abandoned
- 2014-04-15 SG SG10201911353WA patent/SG10201911353WA/en unknown
- 2014-04-15 CA CA2907776A patent/CA2907776C/en active Active
- 2014-04-15 NZ NZ712012A patent/NZ712012A/en unknown
- 2014-04-15 PE PE2021000128A patent/PE20211214A1/en unknown
- 2014-04-15 EP EP20201975.8A patent/EP3800204A1/en active Pending
- 2014-04-15 RU RU2015141520A patent/RU2737727C2/en active
- 2014-04-15 SG SG11201508536PA patent/SG11201508536PA/en unknown
- 2014-04-15 NZ NZ751877A patent/NZ751877A/en unknown
- 2014-04-15 EA EA201591643A patent/EA201591643A1/en unknown
- 2014-04-15 RU RU2019115089A patent/RU2019115089A/en unknown
- 2014-04-15 AU AU2014254086A patent/AU2014254086B2/en active Active
2015
- 2015-09-03 IL IL241103A patent/IL241103B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06594A patent/ZA201506594B/en unknown
- 2015-10-01 MX MX2019005151A patent/MX2019005151A/en unknown
- 2015-10-14 PH PH12015502382A patent/PH12015502382A1/en unknown
- 2015-10-15 CR CR20150576A patent/CR20150576A/en unknown
- 2015-10-15 CL CL2015003049A patent/CL2015003049A1/en unknown
- 2015-12-24 HK HK15112673.2A patent/HK1211948A1/en unknown
2017
- 2017-09-28 CL CL2017002445A patent/CL2017002445A1/en unknown
- 2017-10-19 US US15/788,598 patent/US20180037661A1/en not_active Abandoned
- 2017-10-19 US US15/788,632 patent/US20180037662A1/en not_active Abandoned
- 2017-10-19 US US15/788,574 patent/US9969811B2/en active Active
2018
- 2018-10-05 AU AU2018241141A patent/AU2018241141B2/en active Active
2019
- 2019-07-12 JP JP2019129841A patent/JP2020015719A/en active Pending
- 2019-07-12 US US16/510,287 patent/US20190345258A1/en not_active Abandoned
- 2019-08-06 US US16/533,488 patent/US20200157238A1/en not_active Abandoned
- 2019-08-08 CL CL2019002244A patent/CL2019002244A1/en unknown
- 2019-10-22 AU AU2019253804A patent/AU2019253804A1/en not_active Abandoned
2020
- 2020-06-15 IL IL275398A patent/IL275398A/en unknown
2022
- 2022-06-27 US US17/809,098 patent/US20230047103A1/en active Pending

Also Published As

Publication number	Publication date
PE20211214A1 (en)	2021-07-05
AU2014254086A1 (en)	2015-10-08
CA3071678A1 (en)	2014-10-23
CL2017002445A1 (en)	2018-03-16
US20230047103A1 (en)	2023-02-16
PE20151769A1 (en)	2015-12-11
TWI554284B (en)	2016-10-21
AU2018241141A1 (en)	2018-10-25
US20180037661A1 (en)	2018-02-08
MY173295A (en)	2020-01-14
IL241103A0 (en)	2015-11-30
IL275398A (en)	2020-07-30
SG11201508536PA (en)	2015-11-27
CL2015003049A1 (en)	2016-06-10
EP3800204A1 (en)	2021-04-07
TW201442725A (en)	2014-11-16
CR20150576A (en)	2015-11-20
PH12015502382A1 (en)	2016-02-22
US20180037660A1 (en)	2018-02-08
AU2018241141B2 (en)	2019-11-07
ZA201506594B (en)	2018-11-28
WO2014172371A2 (en)	2014-10-23
CN105121471A (en)	2015-12-02
AU2019253804A1 (en)	2019-11-14
AR095863A1 (en)	2015-11-18
CA2907776C (en)	2020-04-14
IL241103B (en)	2020-07-30
HK1211948A1 (en)	2016-06-03
JP2020015719A (en)	2020-01-30
MX2015013898A (en)	2016-07-08
MA38567A1 (en)	2017-09-29
RU2019115089A (en)	2019-06-11
MX2019005151A (en)	2022-06-27
US20190345258A1 (en)	2019-11-14
US9969811B2 (en)	2018-05-15
MX368259B (en)	2019-09-25
BR112015024926A2 (en)	2017-10-10
JP2016522176A (en)	2016-07-28
KR20200085942A (en)	2020-07-15
US9815904B2 (en)	2017-11-14
NZ712012A (en)	2020-04-24
SG10201911353WA (en)	2020-02-27
NZ751877A (en)	2020-04-24
CL2019002244A1 (en)	2019-11-29
RU2015141520A (en)	2017-05-22
WO2014172371A3 (en)	2015-01-08
CA2907776A1 (en)	2014-10-23
US20140308277A1 (en)	2014-10-16
RU2737727C2 (en)	2020-12-02
US20180037662A1 (en)	2018-02-08
US20200157238A1 (en)	2020-05-21
EP2986643A2 (en)	2016-02-24
AU2014254086B2 (en)	2018-07-05
EA201591643A1 (en)	2016-02-29
KR20150143649A (en)	2015-12-23

Publication	Publication Date	Title
IL283040A (en)	2021-06-30	E-vaping section and e-vaping device
IL275398A (en)	2020-07-30	Pertuzumab variants and evaluation thereof
HK1225715A1 (en)	2017-09-15	Aza-pyridone compounds and uses thereof
IL246439A0 (en)	2016-08-31	Ring-contracted morphinans and the use thereof
GB201317889D0 (en)	2013-11-20	Product and use
GB201305277D0 (en)	2013-05-01	Novel combination and use
HK1221721A1 (en)	2017-06-09	Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones bet
HK1214333A1 (en)	2016-07-22	Bracket and use
GB201313980D0 (en)	2013-09-18	User evaluation
GB201323008D0 (en)	2014-02-12	Compounds and uses thereof
IL244214B (en)	2018-08-30	Thienopiperidine derivative and use thereof
IL240248A0 (en)	2015-09-24	Met-binding agents and uses thereof
IL243433A0 (en)	2016-02-29	Tib2 layres and use thereof
IL244751A0 (en)	2016-04-21	Cyclic thienouracil-carboxamides and use thereof
GB201307233D0 (en)	2013-05-29	Compounds and uses thereof
HK1219962A1 (en)	2017-04-21	Human anti-il-32 antibodies -32
GB201317540D0 (en)	2013-11-20	Sensing
GB201307989D0 (en)	2013-06-12	Novel combinations and use
PL3063333T3 (en)	2018-12-31	Textile run and use thereof
GB201320992D0 (en)	2014-01-15	Complex and uses thereof
GB201315249D0 (en)	2013-10-09	Sensing
GB201306901D0 (en)	2013-05-29	Combination
ZA201601880B (en)	2017-09-27	Hetero-transglycosylase and uses thereof
GB201406964D0 (en)	2014-06-04	Turnstiles
GB201311696D0 (en)	2013-08-14	Assembly and methods